feature	feature_type	alteration_type	alteration	patient_id	ipredict_targeted	score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url
HGF	Copy Number	Amplification		2	1																							
MET	Copy Number	Amplification		2	1	Investigate Actionability	Guideline	Guideline		Investigate Actionability	Crizotinib	MET inhibition	Targeted therapy	"Crizotinib is an available targeted agent with activity against MET amplifications in metastatic, NSCLC."	"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	"Amplification of alternative kinases, such as MET, may suggest resistance to EGFR TKIs."	"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf					
PD-L1 +	IHC			2	0																							
CDK4	Copy Number	Amplification		5	1	Investigate Actionability	Guideline			Investigate Actionability	Palbociclib	CDK4/6 inhibition	Targeted therapy	CDK4 amplification is characteristic of well-differentiated and dedifferentiated liposarcomas. Palbociclib shows activity in this context.	"National Comprehensive Cancer Network. Soft Tissue Sarcoma NCCN Evidence Blocks (Version 1.2021). Accessed November 19th, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf												
MDM2	Copy Number	Amplification		5	0	Investigate Actionability	Preclinical			Investigate Actionability	nutlin-3	MDM2-p53 inhibition	Targeted therapy	Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.	"Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13."	https://doi.org/10.1111/j.1349-7006.2010.01821.x												
WT1	Somatic Variant	Intron		5	0																							
KRAS	Somatic Variant	Missense	p.G12R	7	0	Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
APC	Somatic Variant	Frameshift	p.T664fs*6	9	0																							
KRAS	Somatic Variant	Missense	p.G12S	9	0	Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
TP53	Somatic Variant	Missense	p.R248Q	9	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
CDK4	Copy Number	Amplification		15	1	Investigate Actionability	Guideline			Investigate Actionability	Palbociclib	CDK4/6 inhibition	Targeted therapy	CDK4 amplification is characteristic of well-differentiated and dedifferentiated liposarcomas. Palbociclib shows activity in this context.	"National Comprehensive Cancer Network. Soft Tissue Sarcoma NCCN Evidence Blocks (Version 1.2021). Accessed November 19th, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf												
MDM2	Copy Number	Amplification		15	0	Investigate Actionability	Preclinical			Investigate Actionability	nutlin-3	MDM2-p53 inhibition	Targeted therapy	Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.	"Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13."	https://doi.org/10.1111/j.1349-7006.2010.01821.x												
STAT4	Somatic Variant	Nonsense		15	0																							
BCL2L1	Copy Number	Amplification		19	0																							
KRAS	Somatic Variant	Missense	p.G12A	19	1	Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
PIK3CA	Somatic Variant	Missense	p.E542K	19	0	Putatively Actionable	Preclinical		Clinical trial	Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
SMAD2	Somatic Variant	Nonsense	p.W132*	19	0																							
TP53	Somatic Variant	Missense	p.R175H	19	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
KRAS	Somatic Variant	Missense	p.G12V	20	0	Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
PIK3CA	Somatic Variant	Missense	p.Q546R	20	0	Investigate Actionability	Preclinical		Clinical trial	Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
TP53	Somatic Variant	Nonsense	p.R306*	20	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
APC	Somatic Variant	Nonsense	p.G1499*	22	0																							
APC	Somatic Variant	Nonsense	p.S1400*	22	0																							
CDK6	Copy Number	Amplification		22	0																							
ERBB2	Copy Number	Amplification		22	1	Investigate Actionability	FDA-Approved	Preclinical	Inferential	Investigate Actionability	Ado-Trastuzumab Emtansine	ER signaling inhibition	Hormone therapy	"HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy."	"Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf	Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	"Breast cancer cells with HER2 amplification demonstrate radiation resistance, which can be reversed with trastuzumab."	"Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Molecular cancer therapeutics. 2003; 2(11):1113-20. "	https://mct.aacrjournals.org/content/2/11/1113.long	Investigate Actionability	0	Overexpression and gene amplification of ErbB2 (HER2/neu) is an adverse prognostic indicator associated with aggressive histopathologic parameters and correlated with decreased disease-free survival and overall survival (OS) in breast cancer (BC).	"F Revillion, J Bonneterre, JP Peyrat: ERBB2 oncogene in human breast cancer and its clinical significance Eur J Cancer 34: 791"	https://doi.org/10.1016/S0959-8049(97)10157-5
ERBB2	Somatic Variant	Missense	p.T733I	22	1	Investigate Actionability	Clinical evidence			Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	"Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194."	https://doi.org/10.1038/nature25475												
TP53	Somatic Variant	Missense	p.C135G	22	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
AKT1	Somatic Variant	Missense	p.E17K	23	0	Putatively Actionable	Preclinical			Putatively Actionable	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	"Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51."	https://doi.org/10.1158/1535-7163.MCT-15-0230												
APC	Somatic Variant	Frameshift	p.T1556fs*3	23	0																							
BRAF	Somatic Variant	Missense	p.V600E	23	1	Putatively Actionable	FDA-Approved	Guideline	Guideline	Putatively Actionable	Cetuximab + Encorafenib	EGFR inhibition + B-RAF inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy."	"Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf. Revised April 2020. Accessed October 15, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf
CDKN2A	Somatic Variant	Missense	p.P94L	23	0	Biologically Relevant																						
CDKN2A	Somatic Variant	Nonsense	p.R80*	23	0	Biologically Relevant																						
TERT	Somatic Variant	Promoter	124C>T	23	0																							
TP53	Somatic Variant	Missense	p.R156P	23	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
APC	Somatic Variant	Nonsense	p.E1306*	26	0																							
POLE	Somatic Variant	Missense	p.R446Q	26	0	Investigate Actionability	Inferential		Clinical evidence	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	"Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20."	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	"Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32."	https://doi.org/10.1038/gim.2015.75
SPEN	Somatic Variant	Insertion	p.1750-1insA	26	0																							
SPEN	Somatic Variant	Splice Site	p.1750-2	26	0																							
SPTA1	Somatic Variant	Nonsense	p.R891*	26	0																							
TP53	Somatic Variant	Missense	p.G266V	26	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
AKT1	Somatic Variant	Missense	p.E17K	28	0	Putatively Actionable	Preclinical			Putatively Actionable	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	"Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51."	https://doi.org/10.1158/1535-7163.MCT-15-0230												
BRAF	Somatic Variant	Missense	p.V600E	30	1	Putatively Actionable	FDA-Approved	Guideline	Guideline	Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test."	"Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf
TP53	Somatic Variant	Missense	p.T234C	30	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
CDK4	Copy Number	Amplification		33	0	Investigate Actionability	Guideline			Investigate Actionability	Palbociclib	CDK4/6 inhibition	Targeted therapy	CDK4 amplification is characteristic of well-differentiated and dedifferentiated liposarcomas. Palbociclib shows activity in this context.	"National Comprehensive Cancer Network. Soft Tissue Sarcoma NCCN Evidence Blocks (Version 1.2021). Accessed November 19th, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf												
CDKN2A	Somatic Variant	Frameshift	p.L16fs*9	33	0	Biologically Relevant																						
ERBB2	Copy Number	Amplification		33	1	Investigate Actionability	FDA-Approved	Preclinical	Inferential	Investigate Actionability	Ado-Trastuzumab Emtansine	ER signaling inhibition	Hormone therapy	"HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy."	"Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf	Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	"Breast cancer cells with HER2 amplification demonstrate radiation resistance, which can be reversed with trastuzumab."	"Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Molecular cancer therapeutics. 2003; 2(11):1113-20. "	https://mct.aacrjournals.org/content/2/11/1113.long	Investigate Actionability	0	Overexpression and gene amplification of ErbB2 (HER2/neu) is an adverse prognostic indicator associated with aggressive histopathologic parameters and correlated with decreased disease-free survival and overall survival (OS) in breast cancer (BC).	"F Revillion, J Bonneterre, JP Peyrat: ERBB2 oncogene in human breast cancer and its clinical significance Eur J Cancer 34: 791"	https://doi.org/10.1016/S0959-8049(97)10157-5
ERBB3	Copy Number	Amplification		33	1	Biologically Relevant																						
GLI1	Copy Number	Amplification		33	0																							
KRAS	Somatic Variant	Missense	p.G12R	33	0	Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
TP53	Somatic Variant	Missense	p.R282W	33	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
BCORL1	Somatic Variant	Nonsense	p.Q851*	34	0																							
BRCA2	Somatic Variant	Frameshift	p.M965fs*13	34	0	Investigate Actionability	FDA-Approved	Clinical evidence		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy."	"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	"Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677."	https://doi.org/10.1200/JCO.2016.71.3677					
BRCA2	Somatic Variant	Nonsense	p.S884*	34	0	Investigate Actionability	Clinical evidence	Clinical evidence		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	"Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders."	"Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44."	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	"Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677."	https://doi.org/10.1200/JCO.2016.71.3677					
CDKN2A	Copy Number	Deletion		34	0	Investigate Actionability	Preclinical			Investigate Actionability	EPZ015666	PRMT5 inhibition	Targeted therapy	"These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development"	"Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8."	https://doi.org/10.1126/science.aad5214												
CDKN2B	Copy Number	Deletion		34	0																							
ERBB2	Somatic Variant	Missense	p.I767M	34	0	Investigate Actionability	Clinical evidence			Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	"Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194."	https://doi.org/10.1038/nature25475												
FGFR3	Somatic Variant	Missense	p.S249C	34	1	Putatively Actionable	FDA-Approved			Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	"Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy."	"Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf												
MLL3	Somatic Variant	Nonsense	p.Q2197*	34	0																							
SMAD4	Somatic Variant	Missense	p.D351H	34	0																							
TP53	Somatic Variant	Missense	p.R175H	34	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TMB-Int	Mutational Burden			39	0																							
APC	Somatic Variant	Frameshift	p.T1487fs*17	39	0																							
ARID1B	Somatic Variant	Nonsense	p.R1977*	39	0																							
ERBB4	Somatic Variant	Missense	p.T926M	39	0																							
KRAS	Somatic Variant	Missense	p.G12D	39	0	Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
PIK3CA	Somatic Variant	Missense	p.H1047R	39	0	Putatively Actionable	Preclinical		Clinical trial	Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
SOX9	Somatic Variant	Frameshift	p.T236fs*13	39	0																							
TP53	Somatic Variant	Missense	p.R282W	39	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
ALK	Somatic Variant	Missense	p.R284K	44	0	Investigate Actionability	Preclinical	Preclinical		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	"Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C."	"Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673."	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	"Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C."	"Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673."	https://doi.org/10.1158/2159-8290.CD-13-0846					
CCND1	Copy Number	Amplification		44	0	Investigate Actionability	Inferential		Clinical evidence	Investigate Actionability	Palbociclib	CDK4/6 inhibition	Targeted therapy	"CCND1 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib."	"Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744."	https://doi.org/10.1038/ncomms7744								Investigate Actionability	0	CCND1 amplification showed reduced recurrence-free survival in a randomized control trial of postmenopausal breast cancer patients.	"Bostner, Josefine, et al. ""Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer."" Oncogene 26.49 (2007): 6997-7005."	https://doi.org/10.1038/sj.onc.1210506
CDKN2A	Somatic Variant	Missense	p.D84N	44	0	Biologically Relevant																						
CDKN2A	Somatic Variant	Missense	p.R98Q	44	0	Biologically Relevant																						
ERBB2	Copy Number	Amplification		44	1	Investigate Actionability	FDA-Approved	Preclinical	Inferential	Investigate Actionability	Ado-Trastuzumab Emtansine	ER signaling inhibition	Hormone therapy	"HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy."	"Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf	Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	"Breast cancer cells with HER2 amplification demonstrate radiation resistance, which can be reversed with trastuzumab."	"Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Molecular cancer therapeutics. 2003; 2(11):1113-20. "	https://mct.aacrjournals.org/content/2/11/1113.long	Investigate Actionability	0	Overexpression and gene amplification of ErbB2 (HER2/neu) is an adverse prognostic indicator associated with aggressive histopathologic parameters and correlated with decreased disease-free survival and overall survival (OS) in breast cancer (BC).	"F Revillion, J Bonneterre, JP Peyrat: ERBB2 oncogene in human breast cancer and its clinical significance Eur J Cancer 34: 791"	https://doi.org/10.1016/S0959-8049(97)10157-5
ERBB2	Somatic Variant	Missense	p.S310Y	44	1	Investigate Actionability	Clinical evidence			Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	"Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194."	https://doi.org/10.1038/nature25475												
ERBB3	Somatic Variant	Missense	p.E332K	44	1	Investigate Actionability	Clinical evidence			Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	"Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194."	https://doi.org/10.1038/nature25475												
FGF19	Copy Number	Amplification		44	0																							
FGF4	Copy Number	Amplification		44	0																							
KDM5C	Somatic Variant	Nonsense	p.E1318*	44	0																							
MYCL	Copy Number	Amplification		44	0																							
PIK3CA	Somatic Variant	Missense	p.E545K	44	0	Putatively Actionable	Preclinical		Clinical trial	Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
TERT	Somatic Variant	Promoter	124C>T	44	0																							
TP53	Somatic Variant	Missense	p.E287D	44	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TP533	Somatic Variant	Missense	p.E285K	44	0																							
TSC1	Somatic Variant	Nonsense	p.Q516*	44	0	Investigate Actionability	Clinical evidence			Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	"Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition"	"Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221."	https://doi.org/10.1126/science.1226344												
ASXL1	Somatic Variant	Nonsense	p.Q748*	47	0	Investigate Actionability			Guideline															Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
BRCA1	Somatic Variant	Nonsense	p.E1375*	47	0	Investigate Actionability	FDA-Approved	Clinical evidence		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. "	"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	"Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677."	https://doi.org/10.1200/JCO.2016.71.3677					
CREBBP	Somatic Variant	Nonsense	p.Q1245*	47	0																							
CTNNB1	Somatic Variant	Missense	p.S37F	47	0	Investigate Actionability			Clinical evidence															Investigate Actionability	1	"Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis."	"Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414."	https://doi.org/10.1200/JCO.2009.27.4324
EPHA3	Somatic Variant	Missense	p.T215M	47	0																							
FANCE	Somatic Variant	Missense	p.S241F	47	0																							
FANCL	Somatic Variant	Splice Site	p.692-1G>A	47	0	Investigate Actionability	FDA-Approved			Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone."	"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf												
KDM6A	Somatic Variant	Nonsense	p.S1400*	47	0																							
KEAP1	Somatic Variant	Missense	p.R362Q	47	0	Biologically Relevant																						
LRP1B	Copy Number	Deletion		47	0																							
MAGI2	Somatic Variant	Nonsense	p.R766*	47	0																							
NOTCH1	Somatic Variant	Missense	p.P1770S	47	0																							
NOTCH1	Somatic Variant	Missense	p.T1997M	47	0																							
NOTCH1	Somatic Variant	Nonsense	p.Q1810*	47	0																							
RB1	Somatic Variant	Missense	p.S474N	47	0	Biologically Relevant																						
SETD2	Somatic Variant	Nonsense	p.R1592*	47	0																							
SLIT2	Somatic Variant	Splice Site	p.611+2T>A	47	0																							
SPTA1	Somatic Variant	Missense	p.E1707K	47	0																							
TERT	Somatic Variant	Promoter	146C>T	47	0																							
TMB-High	Mutational Burden			47	1	Investigate Actionability	FDA-Approved			Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	"The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative traetment options."	"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf												
TP53	Somatic Variant	Nonsense	p.R342*	47	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
JUN	Copy Number	Amplification		48	0																							
TP53	Somatic Variant	Missense	p.V157F	48	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
AKT2	Copy Number	Amplification		51	0	Biologically Relevant																						
ARID2	Somatic Variant	Nonsense	p.S889*	51	0																							
BRIP1	Somatic Variant	Nonsense		51	1	Investigate Actionability	FDA-Approved		Inferential	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone."	"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	"Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas."	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287
FRS2	Copy Number	Amplification		51	1																							
MDM2	Copy Number	Amplification		51	0	Investigate Actionability	Preclinical			Investigate Actionability	nutlin-3	MDM2-p53 inhibition	Targeted therapy	Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.	"Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13."	https://doi.org/10.1111/j.1349-7006.2010.01821.x												
MYC	Copy Number	Amplification		51	0	Investigate Actionability			Clinical evidence															Investigate Actionability	0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	"Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13."	https://doi.org/10.1007/s00401-011-0923-y
PIK3CA	Somatic Variant	Unknown		51	0	Investigate Actionability	FDA-Approved		Clinical trial	Investigate Actionability	Alpelisib	PI3K/AKT/mTOR inhibition	Targeted therapy	"Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. "	"Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
RAF1	Copy Number	Amplification		51	0	Biologically Relevant																						
RNF43	Somatic Variant	Nonsense	p.S262*	51	0																							
TMB-High	Mutational Burden			51	0	Investigate Actionability	FDA-Approved			Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	"The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative traetment options."	"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf												
APC	Somatic Variant	Frameshift	p.G1735fs*34	53	1																							
ARID2	Somatic Variant	Nonsense	p.S1057*	53	0																							
ATM	Somatic Variant	Frameshift	p.F2558fs*5	53	1	Investigate Actionability	Clinical trial			Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	"The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects."	"De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007."	https://10.1200/JCO.2019.37.15_suppl.3007												
ATM	Somatic Variant	Nonsense	p.Q445*	53	1	Investigate Actionability	Clinical trial			Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	"The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects."	"De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007."	https://10.1200/JCO.2019.37.15_suppl.3007												
CDK4	Copy Number	Amplification		53	0	Investigate Actionability	Guideline			Investigate Actionability	Palbociclib	CDK4/6 inhibition	Targeted therapy	CDK4 amplification is characteristic of well-differentiated and dedifferentiated liposarcomas. Palbociclib shows activity in this context.	"National Comprehensive Cancer Network. Soft Tissue Sarcoma NCCN Evidence Blocks (Version 1.2021). Accessed November 19th, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf												
FRS2	Copy Number	Amplification		53	0																							
KEAP1	Copy Number	Deletion		53	0	Investigate Actionability		Preclinical									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	"In a mouse model of lung scamous cell carcinoma, deletion of KEAP1 promoted tumor aggressiveness, metastasis, and resistance to oxidative stress and radiotherapy (RT). KEAP1 / NRF2 mutation status predicted risk of local recurrence after RT in patients with non-small lung cancer (NSCLC)."	"Jeong Y, Hoang NT, Lovejoy A, et al. Role of / and Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance Cancer Discov. 2017; 7(1):86-101."	https://doi.org/10.1158/2159-8290.cd-16-0127					
MDM2	Copy Number	Amplification		53	0	Investigate Actionability	Preclinical			Investigate Actionability	nutlin-3	MDM2-p53 inhibition	Targeted therapy	Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.	"Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13."	https://doi.org/10.1111/j.1349-7006.2010.01821.x												
FGF10	Copy Number	Amplification		59	0																							
FRS2	Copy Number	Amplification		59	0																							
GATA6	Copy Number	Amplification		59	0																							
LYN	Copy Number	Amplification		59	0																							
MDM2	Copy Number	Amplification		59	0	Investigate Actionability	Preclinical			Investigate Actionability	nutlin-3	MDM2-p53 inhibition	Targeted therapy	Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.	"Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13."	https://doi.org/10.1111/j.1349-7006.2010.01821.x												
TP53	Somatic Variant	Frameshift	p.H178fs*3	59	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
MAP2K1	Somatic Variant	Missense	p.K57N	61	1	Investigate Actionability	Preclinical	Clinical evidence		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	"Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244)."	"Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8."	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	"Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6."	https://doi.org/10.1073/pnas.0905833106					
NF2	Somatic Variant	Nonsense	p.R466*	61	1																							
TMB-Int	Mutational Burden			66	0																							
CDK12	Somatic Variant	Frameshift	p.L899fs*10	66	0	Investigate Actionability	FDA-Approved			Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone."	"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf												
DNMT3A	Somatic Variant	Missense	p.R882C	66	0	Investigate Actionability			Guideline															Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
FGFR1	Copy Number	Amplification		66	1	Investigate Actionability	Preclinical			Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	"Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33."	https://doi.org/10.1158/2159-8290.CD-12-0210												
PIK3CA	Copy Number	Amplification		66	1	Investigate Actionability	Clinical trial			Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	"A heavily-pretreated, platinum-refractory ovarian cancer patient with PIK3CA amplification achieved radiologically stable disease for four months in a phase 1 clinical trial of pictisilib in solid tumors (RP2D of 330mg daily)."	"Sarker D, Ang JE, Baird R, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(1):77-86."	https://doi.org/10.1158/1078-0432.CCR-14-0947												
TP53	Somatic Variant	Missense	p.R248W	66	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
ZNF703	Copy Number	Amplification		66	0																							
TMB-Int	Mutational Burden			70	1																							
BCOR	Somatic Variant	Nonsense	p.Q224*	70	0	Investigate Actionability			Guideline															Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
BCOR	Somatic Variant	Nonsense	p.Q990*	70	0	Investigate Actionability			Guideline															Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
CTNNB1	Somatic Variant	Missense	p.S37C	70	0	Investigate Actionability			Clinical evidence															Investigate Actionability	1	"Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis."	"Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414."	https://doi.org/10.1200/JCO.2009.27.4324
FBXW7	Somatic Variant	Missense	p.R465H	70	0	Investigate Actionability	Preclinical			Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	"Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway."	"Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502."	https://doi.org/10.1126/science.1162981												
RB1	Somatic Variant	Nonsense	p.E31*	70	0	Biologically Relevant																						
RB1	Somatic Variant	Nonsense	p.S230*	70	0	Biologically Relevant																						
KRAS	Somatic Variant	Missense	p.G12V	72	1	Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
ATRX	Somatic Variant	Frameshift	p.A238fs*19	73	0																							
CDKN2A	Copy Number	Deletion		73	0	Investigate Actionability	Preclinical			Investigate Actionability	EPZ015666	PRMT5 inhibition	Targeted therapy	"These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development"	"Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8."	https://doi.org/10.1126/science.aad5214												
CDKN2B	Copy Number	Deletion		73	0																							
IDH1	Somatic Variant	Missense	p.R132H	73	0	Investigate Actionability	FDA-Approved		Guideline	Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test."	"Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	"National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf
MET	Copy Number	Amplification		73	1	Investigate Actionability	Guideline	Guideline		Investigate Actionability	Crizotinib	MET inhibition	Targeted therapy	"Crizotinib is an available targeted agent with activity against MET amplifications in metastatic, NSCLC."	"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	"Amplification of alternative kinases, such as MET, may suggest resistance to EGFR TKIs."	"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf					
PD-L1 +	IHC			73	0																							
TP53	Somatic Variant	Missense	p.S127Y	73	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
ER+	IHC			74	1																							
KRAS	Somatic Variant	Missense	p.G12V	74	1	Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
RB1	Somatic Variant	Missense	p.V654L	84	0	Biologically Relevant																						
TP53	Somatic Variant	Insertion	p.M160_A161insAIYK	84	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TP53	Somatic Variant	Nonsense	p.Q165*	84	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
AR+	IHC			86	0																							
ER+	IHC			86	1																							
PIK3CA	Somatic Variant	Missense	p.E542K	86	1	Putatively Actionable	Preclinical		Clinical trial	Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
CCNE1	Copy Number	Amplification		88	0	Investigate Actionability	Preclinical			Investigate Actionability	Bortezomib	Proteasome inhibition	Targeted therapy	Sensitivity to Bortezomib was observed in ovarian cancer cell lines.	"Etemadmoghadam, Dariush, et al. ""Synthetic lethality between CCNE1 amplification and loss of BRCA1."" Proceedings of the National Academy of Sciences 110.48 (2013): 19489-19494."	https://doi.org/10.1073/pnas.1314302110												
KRAS	Copy Number	Amplification		88	1	Biologically Relevant																						
PD-L1 +	IHC			88	0																							
TP53	Somatic Variant	Deletion	p.P250_I251del	88	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
BICC2	Rearrangement	Fusion	FGFR2-BICC2	89	0																							
FGFR2	Rearrangement	Fusion	FGFR2-BICC2	89	1	Investigate Actionability	FDA-Approved			Investigate Actionability	Pemigatinib	FGFR inhibition	Targeted therapy	"The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresctable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test."	"Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf. Revised April 2020. Accessed October 15, 2020. "	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf												
POLE	Somatic Variant	Missense	p.R446Q	89	0	Investigate Actionability	Inferential		Clinical evidence	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	"Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20."	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	"Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32."	https://doi.org/10.1038/gim.2015.75
BRCA1	Somatic Variant	Frameshift	p.K519fs*13	91	0	Investigate Actionability	Clinical evidence	Clinical evidence		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Mutations in BRCA1 or BRCA2 may predict sensitivity to PARP inhibition in ovarian cancer	"Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512-9."	https://doi.org/10.1200/JCO.2009.26.9589	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	"Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677."	https://doi.org/10.1200/JCO.2016.71.3677					
TP53	Somatic Variant	Missense	p.H179R	91	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
EWSR1	Rearrangement	Fusion	EWSR1-NFATC2	92	1	Investigate Actionability			Guideline															Investigate Actionability	1	"EWS-FLI1 translocations may be associated with improved prognosis in Ewing's Sarcoma; however, current treatments result in patient outcomes indistinguishable by EWS-FLI1 status."	"National Comprehensive Cancer Network. Bone Cancer (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf. Accessed November 6, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf
MLL2	Somatic Variant	Missense	p.T1246M	92	0																							
NFATC2	Rearrangement	Fusion	EWSR1-NFATC2	92	1																							
BRCA1	Somatic Variant	Frameshift	p.S1253fs*10	94	1	Investigate Actionability	FDA-Approved	Clinical evidence		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. "	"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	"Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677."	https://doi.org/10.1200/JCO.2016.71.3677					
NOTCH1	Somatic Variant	Missense	p.R1586C	94	0																							
PIK3CA	Somatic Variant	Missense	p.C378Y	94	1	Investigate Actionability	Preclinical		Clinical trial	Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
PIK3CA	Somatic Variant	Missense	p.H1047Y	94	1	Putatively Actionable	Preclinical		Clinical trial	Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
SPOP	Somatic Variant	Missense	p.M117V	94	0																							
FANCL	Somatic Variant	Nonsense	p.Q71*	97	0	Investigate Actionability	FDA-Approved			Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone."	"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf												
TMB-Int	Mutational Burden			99	0																							
APC	Somatic Variant	Frameshift	p.P1373fs*10	99	1																							
APC	Somatic Variant	Nonsense	p.K1165*	99	1																							
CDKN2A	Somatic Variant	Missense	p.S73R	99	1	Biologically Relevant																						
KRAS	Somatic Variant	Missense	p.G12D	99	1	Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
SOX9	Somatic Variant	Nonsense	p.Y420*	99	0																							
TP53	Somatic Variant	Missense	p.R110L	99	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
AKT2	Copy Number	Amplification		101	1	Biologically Relevant																						
CCND1	Copy Number	Amplification		101	1	Investigate Actionability	Inferential		Clinical evidence	Investigate Actionability	Palbociclib	CDK4/6 inhibition	Targeted therapy	"CCND1 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib."	"Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744."	https://doi.org/10.1038/ncomms7744								Investigate Actionability	0	CCND1 amplification showed reduced recurrence-free survival in a randomized control trial of postmenopausal breast cancer patients.	"Bostner, Josefine, et al. ""Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer."" Oncogene 26.49 (2007): 6997-7005."	https://doi.org/10.1038/sj.onc.1210506
CDKN2A	Copy Number	Deletion		101	1	Investigate Actionability	Preclinical			Investigate Actionability	EPZ015666	PRMT5 inhibition	Targeted therapy	"These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development"	"Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8."	https://doi.org/10.1126/science.aad5214												
CDKN2B	Copy Number	Deletion		101	1																							
SMAD4	Copy Number	Deletion		101	0																							
TP53	Somatic Variant	Missense	p.R175H	101	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TMB-Int	Mutational Burden			102	1																							
CDKN2A	Copy Number	Deletion		102	1	Investigate Actionability	Preclinical			Investigate Actionability	EPZ015666	PRMT5 inhibition	Targeted therapy	"These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development"	"Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8."	https://doi.org/10.1126/science.aad5214												
CDKN2B	Copy Number	Deletion		102	1																							
EP300	Somatic Variant	Missense	p.P925T	102	0																							
PD-L1 +	IHC			102	1																							
TP53	Somatic Variant	Frameshift	p.D61fs*62	102	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TP53	Somatic Variant	Missense	p.C176F	102	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
CDH1	Somatic Variant	Nonsense	p.Q449*	105	0																							
JAK3	Somatic Variant	Missense	p.R403H	105	0	Investigate Actionability	Preclinical			Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	"Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100."	https://doi.org/10.1182/blood-2014-04-566687												
PIK3CA	Somatic Variant	Missense	p.E545K	105	1	Putatively Actionable	Preclinical		Clinical trial	Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
PTEN	Copy Number	Deletion		105	1	Investigate Actionability	Preclinical	Clinical evidence		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	"Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62."	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	"George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204."	https://doi.org/10.1016/j.immuni.2017.02.001					
TBX3	Somatic Variant	Frameshift	p.D177fs*50	105	0																							
TP53	Somatic Variant	Frameshift	p.R209fs*6	105	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TMB-Int	Mutational Burden			112	1																							
ABL1	Rearrangement	Fusion	NUP214-ABL1	112	0	Investigate Actionability	FDA-Approved			Investigate Actionability	Bosutinib	targets BCR-ABL	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for adult patients with chronic, accelerated, or blast phase Philidelphia chromosome-positive (Ph+) CML with resistance or intolernace to prior therapy."	"Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203441s018lbl.pdf. Revised June 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203441s018lbl.pdf												
CCNE1	Copy Number	Amplification		112	0	Investigate Actionability	Preclinical			Investigate Actionability	Bortezomib	Proteasome inhibition	Targeted therapy	Sensitivity to Bortezomib was observed in ovarian cancer cell lines.	"Etemadmoghadam, Dariush, et al. ""Synthetic lethality between CCNE1 amplification and loss of BRCA1."" Proceedings of the National Academy of Sciences 110.48 (2013): 19489-19494."	https://doi.org/10.1073/pnas.1314302110												
NOTCH1	Somatic Variant	Missense	p.R365C	112	0																							
NUP214	Rearrangement	Fusion	NUP214-ABL1	112	0																							
TP53	Somatic Variant	Missense	p.R248W	112	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TMB-Int	Mutational Burden			115	1																							
APC	Somatic Variant	Frameshift	p.T1556fs*3	115	1																							
APC	Somatic Variant	Nonsense	p.R876*	115	1																							
ATM	Somatic Variant	Frameshift	p.H448fs*36	115	0	Investigate Actionability	Clinical trial			Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	"The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects."	"De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007."	https://10.1200/JCO.2019.37.15_suppl.3007												
DNMT3A	Somatic Variant	Nonsense	p.W860*	115	0	Investigate Actionability			Guideline															Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
KRAS	Somatic Variant	Missense	p.G12V	115	1	Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
PD-L1 +	IHC			115	1																							
PIK3CA	Somatic Variant	Missense	p.I1058F	115	0	Investigate Actionability	Preclinical		Clinical trial	Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
SOX9	Somatic Variant	Frameshift	p.S403fs*1	115	0																							
CDKN2A	Rearrangement	Fusion		118	0	Biologically Relevant																						
KRAS	Somatic Variant	Missense	p.G12V	118	0	Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
TP53	Somatic Variant	Missense	p.R175H	118	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TMB-Int	Mutational Burden			119	0																							
ARID1A	Somatic Variant	Frameshift	p.R1026fs*13	119	0	Investigate Actionability	Preclinical		Clinical evidence	Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	"Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors."	"Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562."	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	"Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744."	https://doi.org/10.1038/ncomms7744
BAP1	Somatic Variant	Missense	p.D672G	119	0																							
CDKN2A	Copy Number	Deletion		119	0	Investigate Actionability	Preclinical			Investigate Actionability	EPZ015666	PRMT5 inhibition	Targeted therapy	"These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development"	"Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8."	https://doi.org/10.1126/science.aad5214												
CDKN2B	Copy Number	Deletion		119	0																							
PTCH1	Somatic Variant	Missense	p.V1131M	119	1																							
AMER1	Somatic Variant	Nonsense	p.R497*	120	0																							
APC	Somatic Variant	Frameshift	p.T1556fs*3	120	0																							
APC	Somatic Variant	Nonsense	p.R283*	120	0																							
BCOR	Somatic Variant	Frameshift	p.V1188fs*12	120	0	Investigate Actionability			Guideline															Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
EPHA7	Somatic Variant	Nonsense	p.R69*	120	0																							
KRAS	Somatic Variant	Missense	p.G13D	120	1	Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
SMAD4	Somatic Variant	Missense	p.P356L	120	1																							
ATM	Somatic Variant	Missense	p.R3008H	121	0	Investigate Actionability	Preclinical			Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	"Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196."	https://doi.org/10.1016/j.tranon.2017.01.007												
BCOR	Somatic Variant	Nonsense	p.S1717*	121	0	Investigate Actionability			Guideline															Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
BRIP1	Somatic Variant	Missense	p.R798Q	121	0	Investigate Actionability	FDA-Approved		Inferential	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone."	"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	"Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas."	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287
CDH1	Somatic Variant	Missense	p.P260L	121	0																							
CDKN1B	Somatic Variant	Splice Site	p.476-1G>T	121	0																							
ERBB2	Somatic Variant	Missense	p.D769H	121	0	Investigate Actionability	Clinical evidence			Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	"Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194."	https://doi.org/10.1038/nature25475												
MAP2K4	Somatic Variant	Missense	p.S184L	121	0																							
MTOR	Somatic Variant	Deletion	p.T1834_T1837del	121	0	Biologically Relevant																						
PIK3CA	Somatic Variant	Missense	p.E545K	121	0	Putatively Actionable	Preclinical		Clinical trial	Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
SMAD4	Somatic Variant	Missense	p.E337K	121	0																							
TMB-High	Mutational Burden			121	1	Investigate Actionability	FDA-Approved			Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	"The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative traetment options."	"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf												
TP53	Somatic Variant	Missense	p.E285Q	121	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TP53	Somatic Variant	Missense	p.R280K	121	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TP53	Somatic Variant	Nonsense	p.E287*	121	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
APC	Somatic Variant	Frameshift	p.E1494fs*13	122	0																							
APC	Somatic Variant	Nonsense	p.R876*	122	0																							
CDKN1B	Somatic Variant	Nonsense	p.Q163*	122	0																							
ERBB2	Copy Number	Amplification		122	0	Investigate Actionability	FDA-Approved	Preclinical	Inferential	Investigate Actionability	Ado-Trastuzumab Emtansine	ER signaling inhibition	Hormone therapy	"HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy."	"Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf	Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	"Breast cancer cells with HER2 amplification demonstrate radiation resistance, which can be reversed with trastuzumab."	"Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Molecular cancer therapeutics. 2003; 2(11):1113-20. "	https://mct.aacrjournals.org/content/2/11/1113.long	Investigate Actionability	0	Overexpression and gene amplification of ErbB2 (HER2/neu) is an adverse prognostic indicator associated with aggressive histopathologic parameters and correlated with decreased disease-free survival and overall survival (OS) in breast cancer (BC).	"F Revillion, J Bonneterre, JP Peyrat: ERBB2 oncogene in human breast cancer and its clinical significance Eur J Cancer 34: 791"	https://doi.org/10.1016/S0959-8049(97)10157-5
ERBB2	Somatic Variant	Missense	p.D769Y	122	1	Investigate Actionability	Clinical evidence			Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	"Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194."	https://doi.org/10.1038/nature25475												
ERBB2	Somatic Variant	Missense	p.S310Y	122	1	Investigate Actionability	Clinical evidence			Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	"Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194."	https://doi.org/10.1038/nature25475												
KRAS	Somatic Variant	Missense	p.G12V	122	0	Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
PARK2	Somatic Variant	Frameshift	p.Q34fs*5	122	0																							
SMAD4	Somatic Variant	Missense	p.V128M	122	1																							
BRAF	Somatic Variant	Missense	p.D594G	123	0	Investigate Actionability	FDA-Approved	Guideline	Guideline	Investigate Actionability	Cetuximab + Encorafenib	EGFR inhibition + B-RAF inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy."	"Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf. Revised April 2020. Accessed October 15, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf
CTNNB1	Somatic Variant	Missense	p.K335I	123	0	Investigate Actionability			Clinical evidence															Investigate Actionability	1	"Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis."	"Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414."	https://doi.org/10.1200/JCO.2009.27.4324
CTNNB1	Somatic Variant	Missense	p.T257I	123	0	Investigate Actionability			Clinical evidence															Investigate Actionability	1	"Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis."	"Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414."	https://doi.org/10.1200/JCO.2009.27.4324
FLT4	Somatic Variant	Missense	p.G71R	123	0																							
MYC	Copy Number	Amplification		123	0	Investigate Actionability			Clinical evidence															Investigate Actionability	0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	"Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13."	https://doi.org/10.1007/s00401-011-0923-y
NRAS	Somatic Variant	Missense	p.G12V	123	0	Putatively Actionable	Clinical evidence		Guideline	Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	"Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46."	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TERT	Somatic Variant	Promoter	124C>T	123	0																							
TP53	Somatic Variant	Missense	p.R175H	123	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
MLL2	Somatic Variant	Frameshift	p.Y2199fs*65	127	0																							
MLL2	Somatic Variant	Nonsense	p.Q2553*	127	0																							
PIK3CA	Somatic Variant	Missense	p.E545K	127	1	Putatively Actionable	Preclinical		Clinical trial	Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
APC	Somatic Variant	Frameshift	p.E1353fs*21	132	0																							
KRAS	Somatic Variant	Missense	p.G12S	132	0	Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
CDKN2A	Copy Number	Deletion		135	0	Investigate Actionability	Preclinical			Investigate Actionability	EPZ015666	PRMT5 inhibition	Targeted therapy	"These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development"	"Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8."	https://doi.org/10.1126/science.aad5214												
EGFR	Copy Number	Amplification		135	0	Investigate Actionability	Clinical evidence			Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.	"Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-37."	https://doi.org/10.1200/JCO.2005.01.0793												
EGFR	Somatic Variant	Missense	p.A289T	135	1	Investigate Actionability	FDA-Approved	Guideline		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	"Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy."	"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	"Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs."	"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf					
EGFR	Somatic Variant	Missense	p.A289V	135	1	Investigate Actionability	FDA-Approved	Guideline		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	"Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy."	"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	"Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs."	"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf					
EGFR	Somatic Variant	Missense	p.R108K	135	1	Investigate Actionability	FDA-Approved	Guideline		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	"Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy."	"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	"Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs."	"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf					
EGFR	Somatic Variant	Missense	p.R324L	135	1	Investigate Actionability	FDA-Approved	Guideline		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	"Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy."	"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	"Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs."	"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf					
EGFRvIII	Somatic Variant	Unknown		135	0																							
KEL	Copy Number	Amplification		135	0																							
MET	Copy Number	Amplification		135	1	Investigate Actionability	Guideline	Guideline		Investigate Actionability	Crizotinib	MET inhibition	Targeted therapy	"Crizotinib is an available targeted agent with activity against MET amplifications in metastatic, NSCLC."	"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	"Amplification of alternative kinases, such as MET, may suggest resistance to EGFR TKIs."	"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf					
TERT	Somatic Variant	Promoter	124C>T	135	0																							
AURKA	Copy Number	Amplification		140	1	Investigate Actionability	Preclinical		Preclinical	Investigate Actionability	Danusertib	Aurora kinase inhibition	Targeted therapy	"Neuroendocrine prostate cancer (NEPC) cell lines shows enhanced sensitivity to pan-Aurora kinase inhibitor therapy, specifically to PHA-739358 (Danusertib)."	"Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487-95."	https://doi.org/10.1158/2159-8290.CD-11-0130								Investigate Actionability	0	Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth	"Sillars-Hardebol, Anke H., et al. ""TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression."" Gut 61.11 (2012): 1568-1575."	https://doi.org/10.1136/gutjnl-2011-301153
GNAS	Copy Number	Amplification		140	0																							
LYN	Copy Number	Amplification		140	0																							
PRKCI	Copy Number	Amplification		140	0																							
TERC	Copy Number	Amplification		140	0																							
TP53	Somatic Variant	Missense	p.R273H	140	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
ZNF217	Copy Number	Amplification		140	0																							
CD274	Copy Number	Amplification		141	1	Investigate Actionability	Inferential			Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab in a trial of 495 patients with non-small cell lung cancer. 	"Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28."	https://doi.org/10.1056/NEJMoa1501824												
CDK4	Copy Number	Amplification		141	0	Investigate Actionability	Guideline			Investigate Actionability	Palbociclib	CDK4/6 inhibition	Targeted therapy	CDK4 amplification is characteristic of well-differentiated and dedifferentiated liposarcomas. Palbociclib shows activity in this context.	"National Comprehensive Cancer Network. Soft Tissue Sarcoma NCCN Evidence Blocks (Version 1.2021). Accessed November 19th, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf												
CDKN2A	Copy Number	Deletion		141	0	Investigate Actionability	Preclinical			Investigate Actionability	EPZ015666	PRMT5 inhibition	Targeted therapy	"These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development"	"Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8."	https://doi.org/10.1126/science.aad5214												
CDKN2B	Copy Number	Deletion		141	0																							
FRS2	Copy Number	Amplification		141	0																							
JAK2	Copy Number	Amplification		141	0	Biologically Relevant																						
KDR	Copy Number	Amplification		141	1																							
KIT	Copy Number	Amplification		141	0	Biologically Relevant																						
MDM2	Copy Number	Amplification		141	0	Investigate Actionability	Preclinical			Investigate Actionability	nutlin-3	MDM2-p53 inhibition	Targeted therapy	Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.	"Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13."	https://doi.org/10.1111/j.1349-7006.2010.01821.x												
MET	Copy Number	Amplification		141	1	Investigate Actionability	Guideline	Guideline		Investigate Actionability	Crizotinib	MET inhibition	Targeted therapy	"Crizotinib is an available targeted agent with activity against MET amplifications in metastatic, NSCLC."	"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	"Amplification of alternative kinases, such as MET, may suggest resistance to EGFR TKIs."	"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf					
PD-L1 +	IHC			141	1																							
PDCD1LG2	Copy Number	Amplification		141	1																							
PDGFRA	Copy Number	Amplification		141	0	Biologically Relevant																						
RB1	Somatic Variant	Splice Site	p.2107-1G>C	141	0	Biologically Relevant																						
EPHA3	Copy Number	Amplification		152	0																							
ERBB2	Copy Number	Amplification		152	1	Investigate Actionability	FDA-Approved	Preclinical	Inferential	Investigate Actionability	Ado-Trastuzumab Emtansine	ER signaling inhibition	Hormone therapy	"HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy."	"Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf	Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	"Breast cancer cells with HER2 amplification demonstrate radiation resistance, which can be reversed with trastuzumab."	"Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Molecular cancer therapeutics. 2003; 2(11):1113-20. "	https://mct.aacrjournals.org/content/2/11/1113.long	Investigate Actionability	0	Overexpression and gene amplification of ErbB2 (HER2/neu) is an adverse prognostic indicator associated with aggressive histopathologic parameters and correlated with decreased disease-free survival and overall survival (OS) in breast cancer (BC).	"F Revillion, J Bonneterre, JP Peyrat: ERBB2 oncogene in human breast cancer and its clinical significance Eur J Cancer 34: 791"	https://doi.org/10.1016/S0959-8049(97)10157-5
MYC	Copy Number	Amplification		152	0	Investigate Actionability			Clinical evidence															Investigate Actionability	0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	"Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13."	https://doi.org/10.1007/s00401-011-0923-y
TP53	Somatic Variant	Missense	p.C176Y	152	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
ACVR1B	Somatic Variant	Missense	p.R257H	155	0																							
ATR	Somatic Variant	Nonsense	p.W2565*	155	0																							
ATRX	Somatic Variant	Nonsense	p.R1739*	155	0																							
CDKN2A	Copy Number	Deletion		155	0	Investigate Actionability	Preclinical			Investigate Actionability	EPZ015666	PRMT5 inhibition	Targeted therapy	"These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development"	"Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8."	https://doi.org/10.1126/science.aad5214												
CDKN2B	Copy Number	Deletion		155	0																							
IDH2	Somatic Variant	Missense	p.R172G	155	0	Investigate Actionability	FDA-Approved		Guideline	Investigate Actionability	Enasidenib	IDH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	"Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf								Investigate Actionability	0	More frequent in Acute Myeloid Leukemia.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
NTRK3	Somatic Variant	Missense	p.I508T	155	0	Biologically Relevant																						
PIK3CA	Somatic Variant	Missense	p.E365K	155	0	Investigate Actionability	Preclinical		Clinical trial	Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
PTEN	Somatic Variant	Missense	p.G129R	155	0	Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	"Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62."	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	"George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204."	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
PTEN	Somatic Variant	Missense	p.P96S	155	0	Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	"Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62."	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	"George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204."	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
TAF1	Somatic Variant	Missense	p.P163L	155	0																							
TMB-High	Mutational Burden			155	1	Investigate Actionability	FDA-Approved			Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	"The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative traetment options."	"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf												
TP53	Somatic Variant	Missense	p.Y205C	155	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TSC1	Somatic Variant	Nonsense	p.W164*	155	0	Investigate Actionability	Clinical evidence			Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	"Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition"	"Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221."	https://doi.org/10.1126/science.1226344												
TMB-Int	Mutational Burden			156	0																							
ERBB2	Copy Number	Amplification		156	1	Investigate Actionability	FDA-Approved	Preclinical	Inferential	Investigate Actionability	Ado-Trastuzumab Emtansine	ER signaling inhibition	Hormone therapy	"HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy."	"Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf	Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	"Breast cancer cells with HER2 amplification demonstrate radiation resistance, which can be reversed with trastuzumab."	"Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Molecular cancer therapeutics. 2003; 2(11):1113-20. "	https://mct.aacrjournals.org/content/2/11/1113.long	Investigate Actionability	0	Overexpression and gene amplification of ErbB2 (HER2/neu) is an adverse prognostic indicator associated with aggressive histopathologic parameters and correlated with decreased disease-free survival and overall survival (OS) in breast cancer (BC).	"F Revillion, J Bonneterre, JP Peyrat: ERBB2 oncogene in human breast cancer and its clinical significance Eur J Cancer 34: 791"	https://doi.org/10.1016/S0959-8049(97)10157-5
TP53	Somatic Variant	Missense	p.G266E	156	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
CCND1	Copy Number	Amplification		157	0	Investigate Actionability	Inferential		Clinical evidence	Investigate Actionability	Palbociclib	CDK4/6 inhibition	Targeted therapy	"CCND1 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib."	"Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744."	https://doi.org/10.1038/ncomms7744								Investigate Actionability	0	CCND1 amplification showed reduced recurrence-free survival in a randomized control trial of postmenopausal breast cancer patients.	"Bostner, Josefine, et al. ""Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer."" Oncogene 26.49 (2007): 6997-7005."	https://doi.org/10.1038/sj.onc.1210506
FGF19	Copy Number	Amplification		157	0																							
FGF3	Copy Number	Amplification		157	0																							
FGF4	Copy Number	Amplification		157	0																							
FGFR1	Copy Number	Amplification		157	0	Investigate Actionability	Preclinical			Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	"Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33."	https://doi.org/10.1158/2159-8290.CD-12-0210												
HRAS	Copy Number	Amplification		157	0																							
MYC	Copy Number	Amplification		157	1	Investigate Actionability			Clinical evidence															Investigate Actionability	0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	"Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13."	https://doi.org/10.1007/s00401-011-0923-y
SF3B1	Copy Number	Amplification		157	0	Biologically Relevant																						
ZNF703	Copy Number	Amplification		157	0																							
TMB-Int	Mutational Burden			162	1																							
DNMT3A	Somatic Variant	Missense	p.R736H	162	0	Investigate Actionability			Guideline															Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
IGH	Rearrangement	Fusion	IGH-ZFP36L1	162	0	Investigate Actionability			Guideline															Investigate Actionability	1	A translocation between 11 and 14 [t(11;14)] has been reported to be associated with improved survival.	"National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf
ZFP36L1	Rearrangement	Fusion	IGH-ZFP36L1	162	0																							
FGFR1	Somatic Variant	Missense	p.K656E	163	1	Biologically Relevant																						
AKT1	Somatic Variant	Missense	p.E17K	A001	0	Putatively Actionable	Preclinical			Putatively Actionable	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	"Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51."	https://doi.org/10.1158/1535-7163.MCT-15-0230												
CCND2	Copy Number	Amplification		A001	0																							
CDKN2A	Copy Number	Deletion		A001	0	Investigate Actionability	Preclinical			Investigate Actionability	EPZ015666	PRMT5 inhibition	Targeted therapy	"These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development"	"Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8."	https://doi.org/10.1126/science.aad5214												
CDKN2B	Copy Number	Deletion		A001	0																							
FGF10	Copy Number	Amplification		A001	0																							
FGF23	Copy Number	Amplification		A001	0																							
FGF6	Copy Number	Amplification		A001	0																							
HGF	Copy Number	Amplification		A001	1																							
KDM5A	Copy Number	Amplification		A001	0																							
KRAS	Copy Number	Amplification		A001	1	Biologically Relevant																						
KRAS	Somatic Variant	Missense	p.G12V	A001	1	Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
MAP2K4	Copy Number	Deletion		A001	0																							
RICTOR	Copy Number	Amplification		A001	0																							
TP53	Somatic Variant	Frameshift	p.I50fs*2	A001	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TMB-Int	Mutational Burden			A003	0																							
BRCA2	Somatic Variant	Frameshift	p.Q2157fs*18	A003	1	Investigate Actionability	FDA-Approved	Clinical evidence		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy."	"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	"Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677."	https://doi.org/10.1200/JCO.2016.71.3677					
ESR1	Somatic Variant	Missense	p.Y537S	A003	0	Investigate Actionability		Clinical evidence									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	"Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane)."	"Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51."	https://doi.org/10.1038/ng.2823					
PALB2	Somatic Variant	Nonsense	p.E180*	A003	1	Investigate Actionability	FDA-Approved		Inferential	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone."	"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	"Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas."	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287
WT1	Somatic Variant	Nonsense	p.K400*	A003	0																							
ARFRP1	Copy Number	Amplification		A004	0																							
ARID1A	Somatic Variant	Nonsense	p.Y229*	A004	0	Investigate Actionability	Preclinical		Clinical evidence	Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	"Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors."	"Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562."	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	"Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744."	https://doi.org/10.1038/ncomms7744
ATM	Somatic Variant	Splice Site	p.2124+1G>T	A004	0	Investigate Actionability	Clinical trial			Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	"The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects."	"De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007."	https://10.1200/JCO.2019.37.15_suppl.3007												
AURKA	Copy Number	Amplification		A004	0	Investigate Actionability	Preclinical		Preclinical	Investigate Actionability	Danusertib	Aurora kinase inhibition	Targeted therapy	"Neuroendocrine prostate cancer (NEPC) cell lines shows enhanced sensitivity to pan-Aurora kinase inhibitor therapy, specifically to PHA-739358 (Danusertib)."	"Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487-95."	https://doi.org/10.1158/2159-8290.CD-11-0130								Investigate Actionability	0	Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth	"Sillars-Hardebol, Anke H., et al. ""TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression."" Gut 61.11 (2012): 1568-1575."	https://doi.org/10.1136/gutjnl-2011-301153
CCND1	Copy Number	Amplification		A004	1	Investigate Actionability	Inferential		Clinical evidence	Investigate Actionability	Palbociclib	CDK4/6 inhibition	Targeted therapy	"CCND1 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib."	"Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744."	https://doi.org/10.1038/ncomms7744								Investigate Actionability	0	CCND1 amplification showed reduced recurrence-free survival in a randomized control trial of postmenopausal breast cancer patients.	"Bostner, Josefine, et al. ""Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer."" Oncogene 26.49 (2007): 6997-7005."	https://doi.org/10.1038/sj.onc.1210506
CDKN2A	Copy Number	Deletion		A004	0	Investigate Actionability	Preclinical			Investigate Actionability	EPZ015666	PRMT5 inhibition	Targeted therapy	"These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development"	"Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8."	https://doi.org/10.1126/science.aad5214												
CDKN2B	Copy Number	Deletion		A004	0																							
EGFR	Copy Number	Amplification		A004	1	Investigate Actionability	Clinical evidence			Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.	"Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-37."	https://doi.org/10.1200/JCO.2005.01.0793												
EMSY	Copy Number	Amplification		A004	0																							
FGF3	Copy Number	Amplification		A004	0																							
FGF4	Copy Number	Amplification		A004	0																							
FGFR1	Copy Number	Amplification		A004	0	Investigate Actionability	Preclinical			Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	"Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33."	https://doi.org/10.1158/2159-8290.CD-12-0210												
GNAS	Copy Number	Amplification		A004	0																							
KAT6A	Copy Number	Amplification		A004	0																							
MYC	Copy Number	Amplification		A004	0	Investigate Actionability			Clinical evidence															Investigate Actionability	0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	"Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13."	https://doi.org/10.1007/s00401-011-0923-y
ZNF217	Copy Number	Amplification		A004	0																							
CDKN2A	Copy Number	Deletion		A008	0	Investigate Actionability	Preclinical			Investigate Actionability	EPZ015666	PRMT5 inhibition	Targeted therapy	"These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development"	"Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8."	https://doi.org/10.1126/science.aad5214												
CDKN2B	Copy Number	Deletion		A008	0																							
ERBB2	Copy Number	Amplification		A008	1	Investigate Actionability	FDA-Approved	Preclinical	Inferential	Investigate Actionability	Ado-Trastuzumab Emtansine	ER signaling inhibition	Hormone therapy	"HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy."	"Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf	Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	"Breast cancer cells with HER2 amplification demonstrate radiation resistance, which can be reversed with trastuzumab."	"Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Molecular cancer therapeutics. 2003; 2(11):1113-20. "	https://mct.aacrjournals.org/content/2/11/1113.long	Investigate Actionability	0	Overexpression and gene amplification of ErbB2 (HER2/neu) is an adverse prognostic indicator associated with aggressive histopathologic parameters and correlated with decreased disease-free survival and overall survival (OS) in breast cancer (BC).	"F Revillion, J Bonneterre, JP Peyrat: ERBB2 oncogene in human breast cancer and its clinical significance Eur J Cancer 34: 791"	https://doi.org/10.1016/S0959-8049(97)10157-5
ERBB3	Somatic Variant	Missense	p.V104L	A008	1	Investigate Actionability	Clinical evidence			Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	"Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194."	https://doi.org/10.1038/nature25475												
TP53	Somatic Variant	Missense	p.R273H	A008	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
BLM	Somatic Variant	Frameshift	p.N515fs*16	A009	0	Investigate Actionability			Clinical evidence															Investigate Actionability	0	"BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance."	"De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060."	https://doi.org/10.1038/srep14060
CCNE1	Copy Number	Amplification		A009	0	Investigate Actionability	Preclinical			Investigate Actionability	Bortezomib	Proteasome inhibition	Targeted therapy	Sensitivity to Bortezomib was observed in ovarian cancer cell lines.	"Etemadmoghadam, Dariush, et al. ""Synthetic lethality between CCNE1 amplification and loss of BRCA1."" Proceedings of the National Academy of Sciences 110.48 (2013): 19489-19494."	https://doi.org/10.1073/pnas.1314302110												
CSF1R	Copy Number	Amplification		A009	0																							
FGFR1	Copy Number	Amplification		A009	1	Investigate Actionability	Preclinical			Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	"Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33."	https://doi.org/10.1158/2159-8290.CD-12-0210												
MLL2	Somatic Variant	Frameshift	p.S3199fs*3	A009	0																							
RAD50	Somatic Variant	Frameshift	p.N934fs*6	A009	0																							
TP53	Somatic Variant	Frameshift	p.K373fs*22+	A009	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TP53	Somatic Variant	Missense	p.R248Q	A009	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
ZNF703	Copy Number	Amplification		A009	0																							
ESR1	Somatic Variant	Missense	p.D538G	A010	1	Investigate Actionability		Clinical evidence									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	"Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane)."	"Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51."	https://doi.org/10.1038/ng.2823					
PIK3R1	Somatic Variant	Missense	p.N564D	A010	1																							
BCOR	Somatic Variant	Missense	p.N1425S	A011	0	Putatively Actionable			Clinical evidence															Putatively Actionable	0	More frequent in Chronic Myelomonocytic Leukemia.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828
CIC	Somatic Variant	Frameshift	p.S1044fs*106	A011	0																							
CTNNB1	Somatic Variant	Missense	p.T41A	A011	1	Investigate Actionability			Clinical evidence															Investigate Actionability	1	"Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis."	"Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414."	https://doi.org/10.1200/JCO.2009.27.4324
GATA2	Somatic Variant	Frameshift	p.G200fs*18	A011	0																							
MLL2	Somatic Variant	Frameshift	p.H3037fs*34	A011	0																							
MSI-High	Microsatellite Stability			A011	1	Investigate Actionability	FDA-Approved	Guideline	Guideline	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	"The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options."	"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf	Investigate Actionability	5-Fluorouracil	Thymidylate synthase inhibition	Chemotherapy	"Patients with MSI-High colorectal cancer appear not to benefit from, and may be resistant to, 5-fluorouracil therapy."	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	1	Patients with MSI-High colorectal cancer often have a favorable prognosis.	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf
PAX5	Somatic Variant	Frameshift	p.Y370fs*23+	A011	0																							
PIK3CA	Somatic Variant	Missense	p.R108H	A011	1	Investigate Actionability	Preclinical		Clinical trial	Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
PIK3R1	Somatic Variant	Frameshift	p.R577fs*3	A011	1																							
PTEN	Somatic Variant	Frameshift	p.V45fs*7	A011	1	Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	"Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62."	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	"George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204."	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
RNF43	Somatic Variant	Frameshift	p.G659fs*41	A011	0																							
TMB-High	Mutational Burden			A011	1	Investigate Actionability	FDA-Approved			Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	"The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative traetment options."	"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf												
MYC	Copy Number	Amplification		A012	0	Investigate Actionability			Clinical evidence															Investigate Actionability	0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	"Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13."	https://doi.org/10.1007/s00401-011-0923-y
TP53	Somatic Variant	Missense	p.K132N	A012	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
AKT2	Copy Number	Amplification		A016	0	Biologically Relevant																						
AURKA	Copy Number	Amplification		A016	0	Investigate Actionability	Preclinical		Preclinical	Investigate Actionability	Danusertib	Aurora kinase inhibition	Targeted therapy	"Neuroendocrine prostate cancer (NEPC) cell lines shows enhanced sensitivity to pan-Aurora kinase inhibitor therapy, specifically to PHA-739358 (Danusertib)."	"Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487-95."	https://doi.org/10.1158/2159-8290.CD-11-0130								Investigate Actionability	0	Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth	"Sillars-Hardebol, Anke H., et al. ""TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression."" Gut 61.11 (2012): 1568-1575."	https://doi.org/10.1136/gutjnl-2011-301153
AXL	Copy Number	Amplification		A016	0																							
CCNE1	Copy Number	Amplification		A016	0	Investigate Actionability	Preclinical			Investigate Actionability	Bortezomib	Proteasome inhibition	Targeted therapy	Sensitivity to Bortezomib was observed in ovarian cancer cell lines.	"Etemadmoghadam, Dariush, et al. ""Synthetic lethality between CCNE1 amplification and loss of BRCA1."" Proceedings of the National Academy of Sciences 110.48 (2013): 19489-19494."	https://doi.org/10.1073/pnas.1314302110												
CD274	Copy Number	Amplification		A016	1	Investigate Actionability	Inferential			Investigate Actionability	Chemotherapy + Pembrolizumab	Chemotherapy + PD-1/PD-L1 inhibition	Combination therapy	The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS>=10) as determined by an FDA approved test. 	"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s088lbl.pdf?utm_source=Salesforce%20Marketing%20Cloud&utm_medium=Email&utm_campaign=												
FLT4	Copy Number	Amplification		A016	0																							
GNAS	Copy Number	Amplification		A016	1																							
JAK2	Copy Number	Amplification		A016	0	Biologically Relevant																						
LYN	Copy Number	Amplification		A016	0																							
MYC	Copy Number	Amplification		A016	0	Investigate Actionability			Clinical evidence															Investigate Actionability	0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	"Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13."	https://doi.org/10.1007/s00401-011-0923-y
PDCD1LG2	Copy Number	Amplification		A016	1																							
PIK3CA	Somatic Variant	Missense	p.H1047R	A016	0	Putatively Actionable	Preclinical		Clinical trial	Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
TP53	Somatic Variant	Deletion	p.E171del	A016	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
CCND2	Copy Number	Amplification		A018	0																							
CD274	Copy Number	Amplification		A018	1	Investigate Actionability	Inferential			Investigate Actionability	Chemotherapy + Pembrolizumab	Chemotherapy + PD-1/PD-L1 inhibition	Combination therapy	The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS>=10) as determined by an FDA approved test. 	"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s088lbl.pdf?utm_source=Salesforce%20Marketing%20Cloud&utm_medium=Email&utm_campaign=												
FGF23	Copy Number	Amplification		A018	0																							
FGF6	Copy Number	Amplification		A018	0																							
JAK2	Copy Number	Amplification		A018	0	Biologically Relevant																						
KAT6A	Copy Number	Amplification		A018	0																							
LZTR1	Copy Number	Amplification		A018	0																							
PDCD1LG2	Copy Number	Amplification		A018	1																							
PRSS8	Copy Number	Amplification		A018	0																							
TP53	Somatic Variant	Splice Site	p.993+1G>A	A018	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TMB-Int	Mutational Burden			A021	0																							
AKT1	Copy Number	Amplification		A021	1	Biologically Relevant																						
ER+	IHC			A021	1																							
FGFR1	Copy Number	Amplification		A021	0	Investigate Actionability	Preclinical			Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	"Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33."	https://doi.org/10.1158/2159-8290.CD-12-0210												
FGFR2	Copy Number	Amplification		A021	1	Investigate Actionability	Preclinical			Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	"Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33."	https://doi.org/10.1158/2159-8290.CD-12-0210												
KAT6A	Copy Number	Amplification		A021	0																							
MLL3	Somatic Variant	Missense	p.R41C	A021	0																							
MYC	Copy Number	Amplification		A021	0	Investigate Actionability			Clinical evidence															Investigate Actionability	0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	"Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13."	https://doi.org/10.1007/s00401-011-0923-y
PIK3CA	Somatic Variant	Missense	p.H1047R	A021	1	Putatively Actionable	Preclinical		Clinical trial	Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
PTEN	Copy Number	Deletion		A021	1	Investigate Actionability	Preclinical	Clinical evidence		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	"Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62."	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	"George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204."	https://doi.org/10.1016/j.immuni.2017.02.001					
RB1	Somatic Variant	Nonsense	p.S576*	A021	0	Biologically Relevant																						
TP53	Somatic Variant	Missense	p.Y205F	A021	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
ZNF703	Copy Number	Amplification		A021	0																							
ATM	Somatic Variant	Nonsense	p.Q1274*	A024	0	Investigate Actionability	Clinical trial			Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	"The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects."	"De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007."	https://10.1200/JCO.2019.37.15_suppl.3007												
CCND2	Copy Number	Amplification		A024	0																							
CDK8	Copy Number	Amplification		A024	0																							
FGF23	Copy Number	Amplification		A024	1																							
FGF6	Copy Number	Amplification		A024	1																							
FGFR1	Copy Number	Amplification		A024	1	Investigate Actionability	Preclinical			Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	"Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33."	https://doi.org/10.1158/2159-8290.CD-12-0210												
FLT3	Copy Number	Amplification		A024	0	Biologically Relevant																						
FRS2	Copy Number	Amplification		A024	1																							
KAT6A	Copy Number	Amplification		A024	0																							
KDM5A	Copy Number	Amplification		A024	0																							
KRAS	Copy Number	Amplification		A024	0	Biologically Relevant																						
MCL1	Copy Number	Amplification		A024	0																							
MDM2	Copy Number	Amplification		A024	0	Investigate Actionability	Preclinical			Investigate Actionability	nutlin-3	MDM2-p53 inhibition	Targeted therapy	Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.	"Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13."	https://doi.org/10.1111/j.1349-7006.2010.01821.x												
MDM4	Copy Number	Amplification		A024	0																							
PIK3C2B	Copy Number	Amplification		A024	0																							
PIK3CA	Somatic Variant	Missense	p.H1047R	A024	1	Putatively Actionable	Preclinical		Clinical trial	Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
ZNF703	Copy Number	Amplification		A024	0																							
CTNNB1	Somatic Variant	Missense	p.S37F	A026	0	Investigate Actionability			Clinical evidence															Investigate Actionability	1	"Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis."	"Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414."	https://doi.org/10.1200/JCO.2009.27.4324
KRAS	Somatic Variant	Missense	p.G12V	A026	1	Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
PIK3CA	Somatic Variant	Missense	p.K111E	A026	1	Investigate Actionability	Preclinical		Clinical trial	Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	"O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83."	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	"Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status."	"Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999."	https://doi.org/10.1200/JCO.2017.75.7310
FAT1	Somatic Variant	Nonsense	P.Y2288*	A032	0																							
TMB-Int	Mutational Burden			A032	0																							
BRAF	Somatic Variant	Missense	p.V600E	A032	1	Putatively Actionable	FDA-Approved	Guideline	Guideline	Putatively Actionable	Cetuximab + Encorafenib	EGFR inhibition + B-RAF inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy."	"Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf. Revised April 2020. Accessed October 15, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf
CCND2	Copy Number	Amplification		A032	0																							
SMAD4	Somatic Variant	Nonsense	p.R445*	A032	1																							
TP53	Somatic Variant	Frameshift	p.V73fs*76	A032	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
ERG	Rearrangement	Fusion	TMPRSS2-ERG	A033	0	Investigate Actionability	Preclinical		Clinical evidence	Investigate Actionability	Rucaparib	PARP inhibition	Targeted therapy	"Cells which harbored the TMPRSS2-ERG fusion became radiosensitive following radiation and PARP inhibitor, specifically Rucaparib."	"Chatterjee P, Choudhary GS, Sharma A, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS ONE. 2013;8(4):e60408."	https://doi.org/10.1371/journal.pone.0060408								Investigate Actionability	0	A cohort of men with localized prostate cancer was followed and a statistically significant association between the presense of the TMPRSS2-ERG fusion and prostate cancer specific death was observed. Prostate cancer with this fusion may be of a more aggressive phenotype.	"Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596-9."	https://doi.org/10.1038/sj.onc.1210237
TMPRSS2	Rearrangement	Fusion	TMPRSS2-ERG	A033	0	Investigate Actionability	Preclinical		Clinical evidence	Investigate Actionability	Rucaparib	PARP inhibition	Targeted therapy	"Cells which harbored the TMPRSS2-ERG fusion became radiosensitive following radiation and PARP inhibitor, specifically Rucaparib."	"Chatterjee P, Choudhary GS, Sharma A, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS ONE. 2013;8(4):e60408."	https://doi.org/10.1371/journal.pone.0060408								Investigate Actionability	0	A cohort of men with localized prostate cancer was followed and a statistically significant association between the presense of the TMPRSS2-ERG fusion and prostate cancer specific death was observed. Prostate cancer with this fusion may be of a more aggressive phenotype.	"Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596-9."	https://doi.org/10.1038/sj.onc.1210237
TP53	Somatic Variant	Missense	p.R175H	A033	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
AURKA	Copy Number	Amplification		A034	0	Investigate Actionability	Preclinical		Preclinical	Investigate Actionability	Danusertib	Aurora kinase inhibition	Targeted therapy	"Neuroendocrine prostate cancer (NEPC) cell lines shows enhanced sensitivity to pan-Aurora kinase inhibitor therapy, specifically to PHA-739358 (Danusertib)."	"Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487-95."	https://doi.org/10.1158/2159-8290.CD-11-0130								Investigate Actionability	0	Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth	"Sillars-Hardebol, Anke H., et al. ""TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression."" Gut 61.11 (2012): 1568-1575."	https://doi.org/10.1136/gutjnl-2011-301153
CCND1	Copy Number	Amplification		A034	1	Investigate Actionability	Inferential		Clinical evidence	Investigate Actionability	Palbociclib	CDK4/6 inhibition	Targeted therapy	"CCND1 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib."	"Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744."	https://doi.org/10.1038/ncomms7744								Investigate Actionability	0	CCND1 amplification showed reduced recurrence-free survival in a randomized control trial of postmenopausal breast cancer patients.	"Bostner, Josefine, et al. ""Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer."" Oncogene 26.49 (2007): 6997-7005."	https://doi.org/10.1038/sj.onc.1210506
FGF19	Copy Number	Amplification		A034	1																							
FGF3	Copy Number	Amplification		A034	1																							
FGF4	Copy Number	Amplification		A034	1																							
GNAS	Copy Number	Amplification		A034	0																							
ZNF217	Copy Number	Amplification		A034	0																							
TMB-Int	Mutational Burden			A035	1																							
KIF5B	Rearrangement	Fusion	KIF5B-RET	A035	1																							
MYC	Copy Number	Amplification		A035	0	Investigate Actionability			Clinical evidence															Investigate Actionability	0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	"Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13."	https://doi.org/10.1007/s00401-011-0923-y
NFKBIA	Copy Number	Amplification		A035	0																							
NKX2-1	Copy Number	Amplification		A035	0																							
PD-L1 +	IHC			A035	1																							
RET	Rearrangement	Fusion	KIF5B-RET	A035	1	Investigate Actionability	FDA-Approved			Investigate Actionability	Selpercatinib	RET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). 	"Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf. Revised May 2020. Accessed October 22, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf												
TP53	Somatic Variant	Nonsense	p.S241*	A035	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
TMB-Int	Mutational Burden			A037	1																							
CDKN2A	Copy Number	Deletion		A037	0	Investigate Actionability	Preclinical			Investigate Actionability	EPZ015666	PRMT5 inhibition	Targeted therapy	"These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development"	"Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8."	https://doi.org/10.1126/science.aad5214												
CDKN2B	Copy Number	Deletion		A037	0																							
KRAS	Somatic Variant	Missense	p.G12C	A037	1	Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Putatively Actionable	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
NF2	Somatic Variant	Nonsense		A037	0																							
TET2	Somatic Variant	Nonsense		A037	0	Investigate Actionability	Guideline			Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf												
TP53	Somatic Variant	Nonsense	p.R306*	A037	0	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
CCNE1	Copy Number	Amplification		A038	0	Investigate Actionability	Preclinical			Investigate Actionability	Bortezomib	Proteasome inhibition	Targeted therapy	Sensitivity to Bortezomib was observed in ovarian cancer cell lines.	"Etemadmoghadam, Dariush, et al. ""Synthetic lethality between CCNE1 amplification and loss of BRCA1."" Proceedings of the National Academy of Sciences 110.48 (2013): 19489-19494."	https://doi.org/10.1073/pnas.1314302110												
MYCL	Copy Number	Amplification		A038	0																							
NOTCH3	Copy Number	Amplification		A038	0																							
TP53	Somatic Variant	Frameshift	p.P191fs*15	A038	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
AKT3	Copy Number	Amplification		A040	0	Biologically Relevant																						
CDK6	Copy Number	Amplification		A040	0																							
EGFR	Copy Number	Amplification		A040	0	Investigate Actionability	Clinical evidence			Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.	"Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-37."	https://doi.org/10.1200/JCO.2005.01.0793												
EGFR	Somatic Variant	Missense	p.G719S	A040	0	Investigate Actionability	FDA-Approved	Guideline		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	"Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy."	"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	"Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs."	"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf					
PAX5	Copy Number	Deletion		A040	0																							
SOX2	Copy Number	Amplification		A040	0																							
TERT	Somatic Variant	Promoter	124C>T	A040	0																							
ER+	IHC			A041	1																							
ERBB2	Copy Number	Amplification		A041	1	Investigate Actionability	FDA-Approved	Preclinical	Inferential	Investigate Actionability	Ado-Trastuzumab Emtansine	ER signaling inhibition	Hormone therapy	"HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy."	"Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf	Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	"Breast cancer cells with HER2 amplification demonstrate radiation resistance, which can be reversed with trastuzumab."	"Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Molecular cancer therapeutics. 2003; 2(11):1113-20. "	https://mct.aacrjournals.org/content/2/11/1113.long	Investigate Actionability	0	Overexpression and gene amplification of ErbB2 (HER2/neu) is an adverse prognostic indicator associated with aggressive histopathologic parameters and correlated with decreased disease-free survival and overall survival (OS) in breast cancer (BC).	"F Revillion, J Bonneterre, JP Peyrat: ERBB2 oncogene in human breast cancer and its clinical significance Eur J Cancer 34: 791"	https://doi.org/10.1016/S0959-8049(97)10157-5
ERBB2	Somatic Variant	Missense	p.E928G	A041	1	Investigate Actionability	Clinical evidence			Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	"Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194."	https://doi.org/10.1038/nature25475												
ERBB2	Somatic Variant	Missense	p.L755S	A041	1	Investigate Actionability	Clinical evidence			Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	"Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194."	https://doi.org/10.1038/nature25475												
TOP2A	Copy Number	Amplification		A041	0																							
TMB-Int	Mutational Burden			A042	0																							
ATM	Somatic Variant	Frameshift	p.C430fs*1	A042	0	Investigate Actionability	Clinical trial			Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	"The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects."	"De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007."	https://10.1200/JCO.2019.37.15_suppl.3007												
ATM	Somatic Variant	Nonsense	p.R2443*	A042	0	Investigate Actionability	Clinical trial			Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	"The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects."	"De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007."	https://10.1200/JCO.2019.37.15_suppl.3007												
BRAF	Somatic Variant	Missense	p.V600E	A042	0	Putatively Actionable	FDA-Approved	Guideline	Guideline	Putatively Actionable	Cetuximab + Encorafenib	EGFR inhibition + B-RAF inhibition	Targeted therapy	"The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy."	"Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf. Revised April 2020. Accessed October 15, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf
APC	Somatic Variant	Nonsense	p.Q1429*	A043	1																							
ERBB3	Somatic Variant	Missense	p.G284R	A043	1	Investigate Actionability	Clinical evidence			Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	"Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194."	https://doi.org/10.1038/nature25475												
KRAS	Somatic Variant	Missense	p.G12V	A043	1	Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
TMB-Int	Mutational Burden			A044	0																							
BCOR	Somatic Variant	Frameshift	p.K1289fs*8	A044	0	Investigate Actionability			Guideline															Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf
FLCN	Somatic Variant	Nonsense	p.W306*	A044	0	Investigate Actionability	Clinical evidence			Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	"Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition"	"Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221."	https://doi.org/10.1126/science.1226344												
TERT	Somatic Variant	Promoter	124C>T	A044	0																							
CDKN2A	Copy Number	Deletion		A045	0	Investigate Actionability	Preclinical			Investigate Actionability	EPZ015666	PRMT5 inhibition	Targeted therapy	"These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development"	"Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8."	https://doi.org/10.1126/science.aad5214												
CDKN2B	Copy Number	Deletion		A045	0																							
KRAS	Somatic Variant	Missense	p.G12D	A045	1	Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	"J Clin Oncol 37, 2019 (suppl; abstr 3003)"	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	"In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control."	"Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9)."	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	"Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157."	https://doi.org/10.1038/ctg.2016.18
SMAD4	Copy Number	Deletion		A045	0																							
TP53	Somatic Variant	Missense	p.V197G	A045	1	Investigate Actionability		Guideline	Guideline								Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	"National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf